Novel Re(I) Complexes as Potential Selective Theranostic Agents in Cancer Cells and <i>In Vivo</i> in <i>Caenorhabditis elegans</i> Tumoral Strains
Alicia Marco, Pezhman Ashoo, Samanta Hernández‐García, Pedro Martínez‐Rodríguez, N. Cutillas, Annette Vollrath, Dustin N. Jordan, Christoph Janiak, Fernando Gandía‐Herrero, José Ruiz
Abstract
High Resolution Image Download MS PowerPoint Slide A series of rhenium(I) complexes of the type fac -[Re(CO) 3 (N^N)L] 0/+, Re1 – Re9, was synthesized, where N^N = benzimidazole-derived bidentate ligand with an ester functionality and L = chloride or pyridine-type ligand. The new compounds demonstrated potent activity toward ovarian A2780 cancer cells. The most active complexes, Re7 – Re9, incorporating 4-NMe 2 py, exhibited remarkable activity in 3D HeLa spheroids. The emission in the red region of Re9, which contains an electron-deficient benzothiazole moiety, allowed its operability as a bioimaging tool for in vitro and in vivo visualization. Re9 effectivity was tested in two different C. elegans tumoral strains, JK1466 and MT2124, to broaden the oncogenic pathways studied. The results showed that Re9 was able to reduce the tumor growth in both strains by increasing the ROS production inside the cells. Moreover, the selectivity of the compound toward cancerous cells was remarkable as it did not affect neither the development nor the progeny of the nematodes.